Kallikrein 9 Antibody (N-term)
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q9UKQ9 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 27513 Da |
Antigen Region | 1-30 aa |
Gene ID | 284366 |
---|---|
Other Names | Kallikrein-9, 3421-, Kallikrein-like protein 3, KLK-L3, KLK9 |
Target/Specificity | This Kallikrein 9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human Kallikrein 9. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | Kallikrein 9 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | KLK9 |
---|---|
Cellular Location | Secreted. |
Tissue Location | Skin, thymus, trachea, cerebellum and spinal cord. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK9 is a novel kallikrein with poptential application for diagnosis, monitoring and therapeutics of various cancers including those of the breast, prostate and testis.
References
Yousef, G.M., et al., Genomics 65(2):184-194 (2000).
Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).
Yousef, G.M., et al., Anticancer Res. 19 (4B), 2843-2852 (1999).
Yousef, G.M., et al., Anticancer Res. 79, 2843-2852 (1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.